UCB SA (OTCMKTS:UCBJY – Get Free Report) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $57.90 and traded as high as $64.18. UCB shares last traded at $64.07, with a volume of 71,706 shares trading hands.
UCB Stock Performance
The business’s 50 day simple moving average is $58.48 and its 200 day simple moving average is $47.35.
UCB Cuts Dividend
The company also recently declared a dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 29th will be paid a dividend of $0.4574 per share. This represents a dividend yield of 0.71%. The ex-dividend date is Friday, April 26th. UCB’s dividend payout ratio (DPR) is presently 46.55%.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Stories
- Five stocks we like better than UCB
- Want to Profit on the Downtrend? Downtrends, Explained.
- Comprehensive Analysis of PayPal Stock
- Do ETFs Pay Dividends? What You Need to Know
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Technology Stocks Explained: Here’s What to Know About Tech
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.